Hydrochlorothiazide And Telmisartan

Introduction Overview

Generic Name

hydrochlorothiazide and telmisartan

Brand Name

Micardis HCT

Dosage Form

oral tablet (12.5 mg-40 mg; 12.5 mg-80 mg; 25 mg-80 mg)

Drug Class

Angiotensin II inhibitors with thiazides

Pharmacokinetics

Absorption:
Hydrochlorothiazide and telmisartan are administered orally and exhibit adequate bioavailability from the gastrointestinal tract. Hydrochlorothiazide, a thiazide diuretic, is rapidly absorbed with peak plasma concentrations generally reached within 1 to 5 hours post-administration. Telmisartan, an angiotensin II receptor blocker (ARB), also shows efficient absorption with peak plasma levels occurring approximately 0.5 to 1 hour after dosing. The presence of food does not significantly affect the bioavailability of either component, enabling flexible administration with or without meals. Clinical studies have confirmed consistent absorption profiles ensuring reliable therapeutic plasma concentrations.

Distribution:
Hydrochlorothiazide distributes moderately into body tissues with an approximate volume of distribution (Vd) of around 0.6 L/kg. It binds to plasma proteins at relatively low affinity (40%). Telmisartan exhibits a high degree of plasma protein binding (>99.5%), primarily to albumin and alpha-1-acid glycoprotein, contributing to its prolonged half-life. The volume of distribution for telmisartan is about 500 liters, reflecting extensive tissue binding, which supports sustained pharmacodynamic effects. Both agents penetrate renal tissues to exert their primary pharmacological effects, while minimal crossing of the blood-brain barrier limits central nervous system side effects.

Metabolism:
Hydrochlorothiazide undergoes negligible hepatic metabolism, being excreted largely unchanged by the kidneys. Telmisartan undergoes minor metabolism predominantly through glucuronidation mediated by uridine diphosphate-glucuronosyltransferases (UGT1A3 and UGT2B7), forming an inactive acyl-glucuronide metabolite. Cytochrome P450 (CYP) enzymes do not significantly contribute to telmisartan metabolism, minimizing drug-drug interaction potential via this pathway. The limited biotransformation of both drugs reduces metabolic load and variability, supporting predictable pharmacokinetics across patient populations.

Elimination:
Renal excretion is the primary elimination route for hydrochlorothiazide, with approximately 60-70% of an administered dose eliminated unchanged in the urine. Its renal clearance slightly exceeds plasma creatinine clearance, reflecting active tubular secretion. Telmisartan is predominantly eliminated via the biliary-fecal route, with less than 3% recovered unchanged in urine. The terminal elimination half-life of hydrochlorothiazide ranges from 6 to 15 hours, whereas telmisartan exhibits a longer half-life of approximately 24 hours, enabling once-daily dosing. Factors such as renal impairment can affect hydrochlorothiazide clearance, necessitating careful monitoring or dose adjustments in compromised patients, while hepatic impairment may influence telmisartan elimination, also requiring clinical vigilance.

Dosage Forms

Available Dosage Forms:
Hydrochlorothiazide and telmisartan are available as oral tablets in the following fixed-dose combinations:
- 12.5 mg hydrochlorothiazide with 40 mg telmisartan
- 12.5 mg hydrochlorothiazide with 80 mg telmisartan
- 25 mg hydrochlorothiazide with 80 mg telmisartan
These tablets are formulated for once-daily administration to optimize hypertension management.

Dosages for Adults and Adolescents:
The recommended dosage for adults with hypertension is typically hydrochlorothiazide 12.5 to 25 mg combined with telmisartan 80 mg orally once daily. Maximum doses may reach hydrochlorothiazide 25 mg with telmisartan 160 mg orally once daily, adjusted based on blood pressure control and tolerance. Dose titration usually begins with lower doses to monitor clinical response and side effects, followed by increases every 2 to 4 weeks as required. This combination is generally not indicated for initial antihypertensive therapy but rather for patients requiring multiple agents.

Specific Patient Populations:
In patients experiencing hypokalemia with hydrochlorothiazide monotherapy, switching to combination therapy with telmisartan 80 mg and hydrochlorothiazide 12.5 mg may mitigate electrolyte imbalances due to telmisartan's potassium-sparing effects. Caution and dose adjustments should be exercised in patients with renal impairment, liver disease, or electrolyte disturbances. The drug is contraindicated in pregnancy due to risk of fetal injury or death during the second and third trimesters and is not recommended for breastfeeding mothers. Pediatric and adolescent use requires careful evaluation without specific dosing approval for initial therapy in this population documented.

Mechanism Of Action

Hydrochlorothiazide and telmisartan combination therapy provides antihypertensive effects through complementary mechanisms addressing different physiological pathways that regulate blood pressure. Hydrochlorothiazide is a thiazide diuretic that acts primarily on the distal convoluted tubules of the nephron in the kidney. It inhibits the sodium-chloride symporter, which reduces sodium and chloride reabsorption, leading to increased excretion of sodium, chloride, and water. This diuretic action decreases extracellular fluid volume, plasma volume, and subsequently cardiac output, contributing to blood pressure reduction. The natriuretic effect also promotes a compensatory renin release which telmisartan counterbalances.

Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor subtype found in vascular smooth muscle and other target tissues. By blocking this receptor, telmisartan reduces vasoconstriction and aldosterone secretion, which leads to vasodilation and decreased sodium and water retention. This interrupts the renin-angiotensin-aldosterone system (RAAS) cascade, which is a key driver of hypertension and cardiovascular remodeling. The inhibition prevents angiotensin II-mediated sympathetic activation and vascular hypertrophy.

Together, the diuretic effect of hydrochlorothiazide reduces plasma volume while telmisartan addresses the hormonal regulation of vascular tone and fluid balance, yielding additive antihypertensive effects. Clinically, this combination improves blood pressure control more effectively than either agent alone, with telmisartan mitigating hydrochlorothiazide-induced potassium loss—a common adverse effect with thiazide diuretics.

Research studies have demonstrated that this combination effectively lowers systolic and diastolic blood pressure and reduces cardiovascular morbidity. Its mechanism comparing favorably to other combination therapies indicates benefits both in efficacy and tolerability. The drug’s ability to target multiple hypertension pathophysiological pathways provides a comprehensive approach to treatment, with robust evidence from controlled trials supporting its clinical use.

Pharmacological Actions

Inhibition of sodium and chloride reabsorption in distal renal tubules by hydrochlorothiazide.
Diuretic effect leading to decreased plasma volume and reduced cardiac output.
Selective blockade of angiotensin II AT1 receptors by telmisartan, preventing vasoconstriction.
Reduction of aldosterone secretion, contributing to natriuresis and decreased fluid retention.
Vasodilation resulting from angiotensin II receptor antagonism.
Mitigation of sympathetic nervous system activation through RAAS inhibition.
Additive antihypertensive effect from combined diuretic and RAAS blockade mechanisms.
Potassium-sparing effect of telmisartan counterbalancing hydrochlorothiazide-induced hypokalemia.
Reduction of arterial pressure and prevention of vascular remodeling.
Improvement of endothelial function through blood pressure normalization.
Maintenance of electrolyte balance due to dual pharmacology.
Longer duration of action from telmisartan allowing once-daily dosing.
Decreased aldosterone-mediated fibrosis and inflammation.
Prevention of target organ damage related to hypertension.
Complementary mechanisms reducing blood pressure with improved tolerability.

Therapeutic Or Clinical Uses

Treatment of essential hypertension to lower elevated blood pressure.
Adjunct therapy for patients inadequately controlled with monotherapy.
Reduction of cardiovascular morbidity associated with hypertension.
Prevention of stroke and myocardial infarction through blood pressure control.
Management of hypertension in patients requiring combination therapy.
Treatment option for hypertensive patients prone to hypokalemia.
Use in patients with salt-sensitive hypertension benefitting from diuretic action.
Maintenance therapy for long-term blood pressure control.
Improvement of compliance via fixed-dose combination therapy.
Use in hypertensive patients with risk factors for cardiovascular disease.
Alternative to other antihypertensive combinations with better side effect profile.
Option for patients intolerant to ACE inhibitors due to cough.
Treatment among individuals with metabolic syndrome requiring blood pressure control.
Use in diabetic hypertensive patients with careful consideration of renal function.
Treatment strategy for resistant hypertension when other agents are insufficient.

Side Or Adverse Effects

Dizziness and light-headedness, especially during initial treatment or dose escalation.
Fatigue or feeling unusually tired.
Nausea and gastrointestinal disturbances including diarrhea.
Back pain reported occasionally in clinical use.
Upper respiratory tract symptoms resembling cold or flu.
Rare but serious allergic reactions including hives and facial swelling.
Muscle pain, tenderness, or weakness potentially indicating rhabdomyolysis.
Signs of electrolyte imbalance such as dry mouth, increased thirst, confusion, or seizures.
Elevated serum creatinine or renal impairment in susceptible patients.
Jaundice or other liver function abnormalities.
Swelling of hands, feet, or unexplained weight gain due to fluid retention.
Easy bruising or abnormal bleeding tendencies.
Eye pain or vision changes warranting immediate medical attention.
Hypotension symptoms including fainting or light-headedness.
Potential increased risk of skin cancer associated with hydrochlorothiazide.

Precautions

Avoid use during pregnancy due to risk of fetal toxicity, especially in second and third trimesters.
Contraindicated in patients unable to produce urine (anuria or severe renal impairment).
Monitor electrolytes periodically due to risk of hypokalemia, hyponatremia, and other imbalances.
Use caution in patients with a history of liver disease.
Inform healthcare providers about history of lupus or autoimmune disorders.
Careful monitoring in diabetic patients as blood glucose control may be affected.
Avoid concomitant use with aliskiren in diabetic or renal impairment patients.
Avoid excessive sun exposure and use sun protection to reduce skin cancer risk with hydrochlorothiazide.
Dosage adjustment may be necessary in elderly patients due to altered pharmacodynamics.
Avoid dehydration risks by maintaining adequate hydration during illness or heat exposure.
Monitor for signs of angioedema or hypersensitivity reactions.
Use caution in patients with electrolyte disturbances, including magnesium abnormalities.
Advise patients to avoid potassium supplements or salt substitutes without medical advice.
Use caution when combined with other antihypertensive agents to prevent hypotension.
Regular blood pressure monitoring required to assess efficacy and side effects.

Warnings

Do not use during pregnancy; risk of injury or death to unborn baby if taken in the second or third trimester.
Discontinue medication immediately if pregnancy is detected.
Risk of severe allergic reactions manifested by swelling of face, lips, tongue, or throat.
May cause symptomatic hypotension; patients should be monitored for dizziness or syncope especially after first dose.
Risk of kidney function deterioration especially in volume-depleted or renal-impaired patients.
Use contraindicated in patients unable to urinate.
Diabetic patients should not combine with aliskiren-containing medications due to increased risk of adverse events.
Can cause electrolyte disturbances such as hypokalemia, hyponatremia, or hyperkalemia.
Potential for rhabdomyolysis which may lead to acute kidney injury, requiring immediate medical attention.
Avoid concurrent use with NSAIDs which may reduce antihypertensive effect and increase renal toxicity.
Use with caution in patients with hepatic impairment due to altered drug metabolism.
Risk of skin cancer is associated with hydrochlorothiazide; regular dermatologic examinations are advised.
Alcohol may potentiate blood pressure lowering effects and increase side effect severity.
Avoid becoming overheated or dehydrated to reduce risk of hypotension and electrolyte imbalance.
Inform surgeon or anesthesiologist of use prior to surgical procedures.

Contraindication

Known hypersensitivity or allergy to hydrochlorothiazide or telmisartan.
Anuria or inability to produce urine.
Pregnancy, particularly during the second and third trimesters.
Concomitant use with aliskiren in patients with diabetes or renal impairment.
History of angioedema related to prior angiotensin receptor blocker therapy.
Severe hepatic impairment or cholestasis.
Known hypersensitivity to sulfonamide-derived drugs due to hydrochlorothiazide component.
Patients with hyperkalemia or significant electrolyte imbalances not corrected prior to treatment.
Severe hypotension or hemodynamic instability.
Concomitant use with other agents causing hyperkalemia without appropriate monitoring.
Pediatric patients without established safety and efficacy data for combination therapy.
Severe renal artery stenosis or bilateral renal artery stenosis.
Patients with untreated or unstable heart failure requiring close supervision.
Use in breastfeeding mothers due to lack of data on drug excretion in human milk.
Use with caution or avoidance in patients with a history of lupus erythematosus exacerbation.

Drug Interactions

Concomitant use with aliskiren-containing medications contraindicated in diabetics or renal impairment.
NSAIDs (including ibuprofen, naproxen, celecoxib) may reduce antihypertensive effects and worsen renal function.
Cholestyramine and colestipol should be administered four hours apart to avoid absorption interference.
Lithium serum levels may increase, requiring monitoring for lithium toxicity.
Digoxin toxicity risk may be elevated due to electrolyte disturbances caused by hydrochlorothiazide.
Corticosteroids and ACTH may increase risk of hypokalemia when used concurrently.
Use with other diuretics can potentiate dehydration and electrolyte imbalances.
Barbiturates and opioid analgesics may increase the risk of hypotension and CNS depression.
Insulin and oral hypoglycemic agents may require dose adjustment due to altered glucose tolerance.
Potassium supplements or potassium-sparing drugs combined with telmisartan increase hyperkalemia risk.
Other antihypertensives may cause additive blood pressure lowering effects and require dose modifications.
Concurrent use with NSAIDs increases risk of kidney injury and diminishes efficacy in hypertension control.
Drugs affecting renal function can alter the elimination of hydrochlorothiazide and telmisartan.
Alcohol may potentiate hypotensive effects and worsen dehydration risk.
Herbal supplements like licorice may antagonize antihypertensive effects or exacerbate potassium loss.

Preparations Of The Drug

Fixed-dose combination oral tablets containing hydrochlorothiazide and telmisartan in defined dosages.
Available strengths: 12.5 mg hydrochlorothiazide with 40 mg telmisartan, 12.5 mg hydrochlorothiazide with 80 mg telmisartan, and 25 mg hydrochlorothiazide with 80 mg telmisartan.
Tablets are film-coated for ease of swallowing and stability.
Supplied in blister packs to protect from moisture and contamination.
Intended for once-daily oral administration.
Not formulated for pediatric use; intended for adult patients.
Storage recommended at room temperature away from heat and moisture.
Preparation for use involves pushing the tablet through the foil without removal from blister until dosing.
No intravenous or alternative parenteral preparations available; strictly oral use.
No dosage forms as liquids or injectables for this fixed-dose combination commercially available.
Combinations designed to enhance patient compliance by reducing pill burden.
Packaging and labeling include dosage information, warnings, and monitoring requirements.
Prescribing information available for healthcare professional guidance.
Generic combination formulations may be available with equivalent dosing.
Patient education materials commonly accompany prescriptions to ensure safe administration.